The global market for Checkpoint Inhibitor Refractory Cancer was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitor Refractory Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitor Refractory Cancer.

The Checkpoint Inhibitor Refractory Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Checkpoint Inhibitor Refractory Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Checkpoint Inhibitor Refractory Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Checkpoint Inhibitor Refractory Cancer Market Report

Report Metric	Details
Report Name	Checkpoint Inhibitor Refractory Cancer Market
CAGR	5%
Segment by Type	PD-1 Inhibitors PD-L1 Inhibitors
Segment by Application	Hodgkin Lymphoma Kidney Cancer Melanoma Non-Small Cell Lung Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bristol-Myers Squibb, AstraZeneca, Merck, Roche, Regeneron Pharmaceuticals, Janssen Research and Development, 4D pharma, 4SC AG, OncoSec Medical, Mirati Therapeutics, Ascentage Pharma Group, ENB Therapeutics, Exicure, Eisai, Kartos Therapeutics, Exelixis, ImmunityBio
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Checkpoint Inhibitor Refractory Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Checkpoint Inhibitor Refractory Cancer Market report?

Ans: The main players in the Checkpoint Inhibitor Refractory Cancer Market are Bristol-Myers Squibb, AstraZeneca, Merck, Roche, Regeneron Pharmaceuticals, Janssen Research and Development, 4D pharma, 4SC AG, OncoSec Medical, Mirati Therapeutics, Ascentage Pharma Group, ENB Therapeutics, Exicure, Eisai, Kartos Therapeutics, Exelixis, ImmunityBio

What are the Application segmentation covered in the Checkpoint Inhibitor Refractory Cancer Market report?

Ans: The Applications covered in the Checkpoint Inhibitor Refractory Cancer Market report are Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-Small Cell Lung Cancer, Others

What are the Type segmentation covered in the Checkpoint Inhibitor Refractory Cancer Market report?

Ans: The Types covered in the Checkpoint Inhibitor Refractory Cancer Market report are PD-1 Inhibitors, PD-L1 Inhibitors

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 PD-1 Inhibitors

1.2.3 PD-L1 Inhibitors

1.3 Market by Application

1.3.1 Global Checkpoint Inhibitor Refractory Cancer Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hodgkin Lymphoma

1.3.3 Kidney Cancer

1.3.4 Melanoma

1.3.5 Non-Small Cell Lung Cancer

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Checkpoint Inhibitor Refractory Cancer Market Perspective (2020-2031)

2.2 Global Checkpoint Inhibitor Refractory Cancer Growth Trends by Region

2.2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Checkpoint Inhibitor Refractory Cancer Historic Market Size by Region (2020-2025)

2.2.3 Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Region (2026-2031)

2.3 Checkpoint Inhibitor Refractory Cancer Market Dynamics

2.3.1 Checkpoint Inhibitor Refractory Cancer Industry Trends

2.3.2 Checkpoint Inhibitor Refractory Cancer Market Drivers

2.3.3 Checkpoint Inhibitor Refractory Cancer Market Challenges

2.3.4 Checkpoint Inhibitor Refractory Cancer Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Checkpoint Inhibitor Refractory Cancer Players by Revenue

3.1.1 Global Top Checkpoint Inhibitor Refractory Cancer Players by Revenue (2020-2025)

3.1.2 Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Players (2020-2025)

3.2 Global Checkpoint Inhibitor Refractory Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Checkpoint Inhibitor Refractory Cancer Revenue

3.4 Global Checkpoint Inhibitor Refractory Cancer Market Concentration Ratio

3.4.1 Global Checkpoint Inhibitor Refractory Cancer Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Checkpoint Inhibitor Refractory Cancer Revenue in 2024

3.5 Global Key Players of Checkpoint Inhibitor Refractory Cancer Head office and Area Served

3.6 Global Key Players of Checkpoint Inhibitor Refractory Cancer, Product and Application

3.7 Global Key Players of Checkpoint Inhibitor Refractory Cancer, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Checkpoint Inhibitor Refractory Cancer Breakdown Data by Type

4.1 Global Checkpoint Inhibitor Refractory Cancer Historic Market Size by Type (2020-2025)

4.2 Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Type (2026-2031)

5 Checkpoint Inhibitor Refractory Cancer Breakdown Data by Application

5.1 Global Checkpoint Inhibitor Refractory Cancer Historic Market Size by Application (2020-2025)

5.2 Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Checkpoint Inhibitor Refractory Cancer Market Size (2020-2031)

6.2 North America Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2020-2025)

6.4 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Checkpoint Inhibitor Refractory Cancer Market Size (2020-2031)

7.2 Europe Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2020-2025)

7.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size (2020-2031)

8.2 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2020-2025)

8.4 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Checkpoint Inhibitor Refractory Cancer Market Size (2020-2031)

9.2 Latin America Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2020-2025)

9.4 Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size (2020-2031)

10.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2020-2025)

10.4 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bristol-Myers Squibb

11.1.1 Bristol-Myers Squibb Company Details

11.1.2 Bristol-Myers Squibb Business Overview

11.1.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Introduction

11.1.4 Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.1.5 Bristol-Myers Squibb Recent Development

11.2 AstraZeneca

11.2.1 AstraZeneca Company Details

11.2.2 AstraZeneca Business Overview

11.2.3 AstraZeneca Checkpoint Inhibitor Refractory Cancer Introduction

11.2.4 AstraZeneca Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.2.5 AstraZeneca Recent Development

11.3 Merck

11.3.1 Merck Company Details

11.3.2 Merck Business Overview

11.3.3 Merck Checkpoint Inhibitor Refractory Cancer Introduction

11.3.4 Merck Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.3.5 Merck Recent Development

11.4 Roche

11.4.1 Roche Company Details

11.4.2 Roche Business Overview

11.4.3 Roche Checkpoint Inhibitor Refractory Cancer Introduction

11.4.4 Roche Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.4.5 Roche Recent Development

11.5 Regeneron Pharmaceuticals

11.5.1 Regeneron Pharmaceuticals Company Details

11.5.2 Regeneron Pharmaceuticals Business Overview

11.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Introduction

11.5.4 Regeneron Pharmaceuticals Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.5.5 Regeneron Pharmaceuticals Recent Development

11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Details

11.6.2 Bristol-Myers Squibb Business Overview

11.6.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Introduction

11.6.4 Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.6.5 Bristol-Myers Squibb Recent Development

11.7 Janssen Research and Development

11.7.1 Janssen Research and Development Company Details

11.7.2 Janssen Research and Development Business Overview

11.7.3 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Introduction

11.7.4 Janssen Research and Development Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.7.5 Janssen Research and Development Recent Development

11.8 4D pharma

11.8.1 4D pharma Company Details

11.8.2 4D pharma Business Overview

11.8.3 4D pharma Checkpoint Inhibitor Refractory Cancer Introduction

11.8.4 4D pharma Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.8.5 4D pharma Recent Development

11.9 4SC AG

11.9.1 4SC AG Company Details

11.9.2 4SC AG Business Overview

11.9.3 4SC AG Checkpoint Inhibitor Refractory Cancer Introduction

11.9.4 4SC AG Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.9.5 4SC AG Recent Development

11.10 OncoSec Medical

11.10.1 OncoSec Medical Company Details

11.10.2 OncoSec Medical Business Overview

11.10.3 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Introduction

11.10.4 OncoSec Medical Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.10.5 OncoSec Medical Recent Development

11.11 Mirati Therapeutics

11.11.1 Mirati Therapeutics Company Details

11.11.2 Mirati Therapeutics Business Overview

11.11.3 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction

11.11.4 Mirati Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.11.5 Mirati Therapeutics Recent Development

11.12 Ascentage Pharma Group

11.12.1 Ascentage Pharma Group Company Details

11.12.2 Ascentage Pharma Group Business Overview

11.12.3 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Introduction

11.12.4 Ascentage Pharma Group Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.12.5 Ascentage Pharma Group Recent Development

11.13 ENB Therapeutics

11.13.1 ENB Therapeutics Company Details

11.13.2 ENB Therapeutics Business Overview

11.13.3 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction

11.13.4 ENB Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.13.5 ENB Therapeutics Recent Development

11.14 Exicure

11.14.1 Exicure Company Details

11.14.2 Exicure Business Overview

11.14.3 Exicure Checkpoint Inhibitor Refractory Cancer Introduction

11.14.4 Exicure Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.14.5 Exicure Recent Development

11.15 Eisai

11.15.1 Eisai Company Details

11.15.2 Eisai Business Overview

11.15.3 Eisai Checkpoint Inhibitor Refractory Cancer Introduction

11.15.4 Eisai Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.15.5 Eisai Recent Development

11.16 Kartos Therapeutics

11.16.1 Kartos Therapeutics Company Details

11.16.2 Kartos Therapeutics Business Overview

11.16.3 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction

11.16.4 Kartos Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.16.5 Kartos Therapeutics Recent Development

11.17 Exelixis

11.17.1 Exelixis Company Details

11.17.2 Exelixis Business Overview

11.17.3 Exelixis Checkpoint Inhibitor Refractory Cancer Introduction

11.17.4 Exelixis Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.17.5 Exelixis Recent Development

11.18 ImmunityBio

11.18.1 ImmunityBio Company Details

11.18.2 ImmunityBio Business Overview

11.18.3 ImmunityBio Checkpoint Inhibitor Refractory Cancer Introduction

11.18.4 ImmunityBio Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

11.18.5 ImmunityBio Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Merck

Roche

Regeneron Pharmaceuticals

4D Pharma

4SC AG

Mirati Therapeutics

Ascentage Pharma Group

Janssen Research and Development

List of Tables

Table 1. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of PD-1 Inhibitors

Table 3. Key Players of PD-L1 Inhibitors

Table 4. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Checkpoint Inhibitor Refractory Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Checkpoint Inhibitor Refractory Cancer Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region (2020-2025)

Table 8. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region (2026-2031)

Table 10. Checkpoint Inhibitor Refractory Cancer Market Trends

Table 11. Checkpoint Inhibitor Refractory Cancer Market Drivers

Table 12. Checkpoint Inhibitor Refractory Cancer Market Challenges

Table 13. Checkpoint Inhibitor Refractory Cancer Market Restraints

Table 14. Global Checkpoint Inhibitor Refractory Cancer Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Checkpoint Inhibitor Refractory Cancer Market Share by Players (2020-2025)

Table 16. Global Top Checkpoint Inhibitor Refractory Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2024)

Table 17. Ranking of Global Top Checkpoint Inhibitor Refractory Cancer Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Checkpoint Inhibitor Refractory Cancer, Headquarters and Area Served

Table 20. Global Key Players of Checkpoint Inhibitor Refractory Cancer, Product and Application

Table 21. Global Key Players of Checkpoint Inhibitor Refractory Cancer, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Checkpoint Inhibitor Refractory Cancer Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Type (2020-2025)

Table 25. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Type (2026-2031)

Table 27. Global Checkpoint Inhibitor Refractory Cancer Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Application (2020-2025)

Table 29. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Application (2026-2031)

Table 31. North America Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 46. Bristol-Myers Squibb Company Details

Table 47. Bristol-Myers Squibb Business Overview

Table 48. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product

Table 49. Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 50. Bristol-Myers Squibb Recent Development

Table 51. AstraZeneca Company Details

Table 52. AstraZeneca Business Overview

Table 53. AstraZeneca Checkpoint Inhibitor Refractory Cancer Product

Table 54. AstraZeneca Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 55. AstraZeneca Recent Development

Table 56. Merck Company Details

Table 57. Merck Business Overview

Table 58. Merck Checkpoint Inhibitor Refractory Cancer Product

Table 59. Merck Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 60. Merck Recent Development

Table 61. Roche Company Details

Table 62. Roche Business Overview

Table 63. Roche Checkpoint Inhibitor Refractory Cancer Product

Table 64. Roche Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 65. Roche Recent Development

Table 66. Regeneron Pharmaceuticals Company Details

Table 67. Regeneron Pharmaceuticals Business Overview

Table 68. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product

Table 69. Regeneron Pharmaceuticals Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 70. Regeneron Pharmaceuticals Recent Development

Table 71. Bristol-Myers Squibb Company Details

Table 72. Bristol-Myers Squibb Business Overview

Table 73. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product

Table 74. Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 75. Bristol-Myers Squibb Recent Development

Table 76. Janssen Research and Development Company Details

Table 77. Janssen Research and Development Business Overview

Table 78. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product

Table 79. Janssen Research and Development Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 80. Janssen Research and Development Recent Development

Table 81. 4D pharma Company Details

Table 82. 4D pharma Business Overview

Table 83. 4D pharma Checkpoint Inhibitor Refractory Cancer Product

Table 84. 4D pharma Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 85. 4D pharma Recent Development

Table 86. 4SC AG Company Details

Table 87. 4SC AG Business Overview

Table 88. 4SC AG Checkpoint Inhibitor Refractory Cancer Product

Table 89. 4SC AG Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 90. 4SC AG Recent Development

Table 91. OncoSec Medical Company Details

Table 92. OncoSec Medical Business Overview

Table 93. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product

Table 94. OncoSec Medical Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 95. OncoSec Medical Recent Development

Table 96. Mirati Therapeutics Company Details

Table 97. Mirati Therapeutics Business Overview

Table 98. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product

Table 99. Mirati Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 100. Mirati Therapeutics Recent Development

Table 101. Ascentage Pharma Group Company Details

Table 102. Ascentage Pharma Group Business Overview

Table 103. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product

Table 104. Ascentage Pharma Group Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 105. Ascentage Pharma Group Recent Development

Table 106. ENB Therapeutics Company Details

Table 107. ENB Therapeutics Business Overview

Table 108. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product

Table 109. ENB Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 110. ENB Therapeutics Recent Development

Table 111. Exicure Company Details

Table 112. Exicure Business Overview

Table 113. Exicure Checkpoint Inhibitor Refractory Cancer Product

Table 114. Exicure Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 115. Exicure Recent Development

Table 116. Eisai Company Details

Table 117. Eisai Business Overview

Table 118. Eisai Checkpoint Inhibitor Refractory Cancer Product

Table 119. Eisai Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 120. Eisai Recent Development

Table 121. Kartos Therapeutics Company Details

Table 122. Kartos Therapeutics Business Overview

Table 123. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product

Table 124. Kartos Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 125. Kartos Therapeutics Recent Development

Table 126. Exelixis Company Details

Table 127. Exelixis Business Overview

Table 128. Exelixis Checkpoint Inhibitor Refractory Cancer Product

Table 129. Exelixis Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 130. Exelixis Recent Development

Table 131. ImmunityBio Company Details

Table 132. ImmunityBio Business Overview

Table 133. ImmunityBio Checkpoint Inhibitor Refractory Cancer Product

Table 134. ImmunityBio Revenue in Checkpoint Inhibitor Refractory Cancer Business (2020-2025) & (US$ Million)

Table 135. ImmunityBio Recent Development

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

Table 139. Authors List of This Report

List of Figures

Figure 1. Checkpoint Inhibitor Refractory Cancer Picture

Figure 2. Global Checkpoint Inhibitor Refractory Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Checkpoint Inhibitor Refractory Cancer Market Share by Type: 2024 VS 2031

Figure 4. PD-1 Inhibitors Features

Figure 5. PD-L1 Inhibitors Features

Figure 6. Global Checkpoint Inhibitor Refractory Cancer Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Checkpoint Inhibitor Refractory Cancer Market Share by Application: 2024 VS 2031

Figure 8. Hodgkin Lymphoma Case Studies

Figure 9. Kidney Cancer Case Studies

Figure 10. Melanoma Case Studies

Figure 11. Non-Small Cell Lung Cancer Case Studies

Figure 12. Others Case Studies

Figure 13. Checkpoint Inhibitor Refractory Cancer Report Years Considered

Figure 14. Global Checkpoint Inhibitor Refractory Cancer Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Checkpoint Inhibitor Refractory Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region: 2024 VS 2031

Figure 17. Global Checkpoint Inhibitor Refractory Cancer Market Share by Players in 2024

Figure 18. Global Top Checkpoint Inhibitor Refractory Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue in 2024

Figure 20. North America Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Checkpoint Inhibitor Refractory Cancer Market Share by Country (2020-2031)

Figure 22. United States Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Checkpoint Inhibitor Refractory Cancer Market Share by Country (2020-2031)

Figure 26. Germany Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Share by Region (2020-2031)

Figure 34. China Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Checkpoint Inhibitor Refractory Cancer Market Share by Country (2020-2031)

Figure 42. Mexico Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Share by Country (2020-2031)

Figure 46. Turkey Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 50. AstraZeneca Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 51. Merck Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 52. Roche Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 53. Regeneron Pharmaceuticals Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 55. Janssen Research and Development Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 56. 4D pharma Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 57. 4SC AG Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 58. OncoSec Medical Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 59. Mirati Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 60. Ascentage Pharma Group Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 61. ENB Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 62. Exicure Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 63. Eisai Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 64. Kartos Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 65. Exelixis Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 66. ImmunityBio Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2020-2025)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions